Diferencia entre revisiones de «Bismuth subsalicylate»
(Prepared the page for translation) |
|||
| Línea 1: | Línea 1: | ||
<languages/> | |||
<translate> | |||
==Administration== | ==Administration== | ||
*Type: Anti-[[diarrhea]]l | |||
*Type: Anti-[[Special:MyLanguage/diarrhea|diarrhea]]l | |||
*Dosage Forms: | *Dosage Forms: | ||
*Routes of Administration: PO | *Routes of Administration: PO | ||
*Common Trade Names: Pepto Bismol, Maalox | *Common Trade Names: Pepto Bismol, Maalox | ||
==Adult Dosing== | ==Adult Dosing== | ||
*[[Diarrhea]], gas, indigestion, heartburn, [[nausea]]: 524mg (2 tabs regular strength) PO q30m PRN, max 8 doses regular strength or 4 doses extra-strength daily | |||
*[[H. pylori]]: 524mg (2 regular-strength tablets or 1 extra-strength tablet) + 250 mg metronidazole + 500 mg tetracycline PO q6hr x14d, plus H2 antagonist | *[[Special:MyLanguage/Diarrhea|Diarrhea]], gas, indigestion, heartburn, [[Special:MyLanguage/nausea|nausea]]: 524mg (2 tabs regular strength) PO q30m PRN, max 8 doses regular strength or 4 doses extra-strength daily | ||
*[[Special:MyLanguage/H. pylori|H. pylori]]: 524mg (2 regular-strength tablets or 1 extra-strength tablet) + 250 mg metronidazole + 500 mg tetracycline PO q6hr x14d, plus H2 antagonist | |||
==Pediatric Dosing== | ==Pediatric Dosing== | ||
*<3y: safety/efficacy not established | *<3y: safety/efficacy not established | ||
*2-6y: 87mg PO q30-60m PRN | *2-6y: 87mg PO q30-60m PRN | ||
| Línea 15: | Línea 23: | ||
*9-12y: 262mg PO q30-60m PRN | *9-12y: 262mg PO q30-60m PRN | ||
*>12y: adult dose | *>12y: adult dose | ||
==Special Populations== | ==Special Populations== | ||
===[[Drug pregnancy categories|Pregnancy Rating]]=== | |||
===[[Special:MyLanguage/Drug pregnancy categories|Pregnancy Rating]]=== | |||
*Category C, Category D in 3rd trimester | *Category C, Category D in 3rd trimester | ||
===Lactation risk=== | ===Lactation risk=== | ||
*Salicylates enter breastmilk; use with caution | *Salicylates enter breastmilk; use with caution | ||
===Renal Dosing=== | ===Renal Dosing=== | ||
*Caution: overdose may cause nephrotoxicity | *Caution: overdose may cause nephrotoxicity | ||
===Hepatic Dosing=== | ===Hepatic Dosing=== | ||
==Contraindications== | ==Contraindications== | ||
*Allergy to class/drug | *Allergy to class/drug | ||
*Infectious diarrhea (fever) | *Infectious diarrhea (fever) | ||
*von Willebrand disease, hemorrhage, ulcer, GI bleeding, hemophilia | *von Willebrand disease, hemorrhage, ulcer, GI bleeding, hemophilia | ||
*In pediatric patients; chicken pox or influenza (risk of [[Reye syndrome]]) | *In pediatric patients; chicken pox or influenza (risk of [[Special:MyLanguage/Reye syndrome|Reye syndrome]]) | ||
==Adverse Reactions== | ==Adverse Reactions== | ||
===Serious=== | ===Serious=== | ||
*Duodenal ulcer, GI hemorrhage | *Duodenal ulcer, GI hemorrhage | ||
*Neurotoxicity | *Neurotoxicity | ||
*Renal failure | *Renal failure | ||
===Common=== | ===Common=== | ||
*Nausea, diarrhea, abdominal pain, constipation, anorexia, dyspepsia, flatulence, anal discomfort | *Nausea, diarrhea, abdominal pain, constipation, anorexia, dyspepsia, flatulence, anal discomfort | ||
*Black stool, melena | *Black stool, melena | ||
| Línea 51: | Línea 76: | ||
*Tinnitus | *Tinnitus | ||
*Muscle spasm | *Muscle spasm | ||
==Pharmacology== | ==Pharmacology== | ||
*Half-life: Bismuth- 21-72 days, salicylate- 2.5h | *Half-life: Bismuth- 21-72 days, salicylate- 2.5h | ||
*Metabolism: GI tract, liver | *Metabolism: GI tract, liver | ||
*Excretion: Bismuth- feces, salicylate- urine | *Excretion: Bismuth- feces, salicylate- urine | ||
==Mechanism of Action== | ==Mechanism of Action== | ||
*Bismuth: antimicrobial, anti-inflammatory action | *Bismuth: antimicrobial, anti-inflammatory action | ||
*Salicylate: antisecretory effect | *Salicylate: antisecretory effect | ||
==Comments== | ==Comments== | ||
| Línea 65: | Línea 95: | ||
==See Also== | ==See Also== | ||
*[[Bismuth toxicity]] | |||
*[[Special:MyLanguage/Bismuth toxicity|Bismuth toxicity]] | |||
==References== | ==References== | ||
https://reference.medscape.com/drug/kaopectate-pepto-bismol-bismuth-subsalicylate-342037#10 | https://reference.medscape.com/drug/kaopectate-pepto-bismol-bismuth-subsalicylate-342037#10 | ||
<references/> | <references/> | ||
| Línea 73: | Línea 106: | ||
[[Category:Pharmacology]] | [[Category:Pharmacology]] | ||
[[Category:GI]] | [[Category:GI]] | ||
</translate> | |||
Revisión del 21:44 4 ene 2026
Administration
- Type: Anti-diarrheal
- Dosage Forms:
- Routes of Administration: PO
- Common Trade Names: Pepto Bismol, Maalox
Adult Dosing
- Diarrhea, gas, indigestion, heartburn, nausea: 524mg (2 tabs regular strength) PO q30m PRN, max 8 doses regular strength or 4 doses extra-strength daily
- H. pylori: 524mg (2 regular-strength tablets or 1 extra-strength tablet) + 250 mg metronidazole + 500 mg tetracycline PO q6hr x14d, plus H2 antagonist
Pediatric Dosing
- <3y: safety/efficacy not established
- 2-6y: 87mg PO q30-60m PRN
- 6-9y: 175mg PO q30-60m PRN
- 9-12y: 262mg PO q30-60m PRN
- >12y: adult dose
Special Populations
Pregnancy Rating
- Category C, Category D in 3rd trimester
Lactation risk
- Salicylates enter breastmilk; use with caution
Renal Dosing
- Caution: overdose may cause nephrotoxicity
Hepatic Dosing
Contraindications
- Allergy to class/drug
- Infectious diarrhea (fever)
- von Willebrand disease, hemorrhage, ulcer, GI bleeding, hemophilia
- In pediatric patients; chicken pox or influenza (risk of Reye syndrome)
Adverse Reactions
Serious
- Duodenal ulcer, GI hemorrhage
- Neurotoxicity
- Renal failure
Common
- Nausea, diarrhea, abdominal pain, constipation, anorexia, dyspepsia, flatulence, anal discomfort
- Black stool, melena
- URI, sinusitis
- Asthenia
- Discolored tongue, taste perversion
- Headache, dizziness
- Paresthesia
- Anxiety, depression
- Tinnitus
- Muscle spasm
Pharmacology
- Half-life: Bismuth- 21-72 days, salicylate- 2.5h
- Metabolism: GI tract, liver
- Excretion: Bismuth- feces, salicylate- urine
Mechanism of Action
- Bismuth: antimicrobial, anti-inflammatory action
- Salicylate: antisecretory effect
Comments
See Also
References
https://reference.medscape.com/drug/kaopectate-pepto-bismol-bismuth-subsalicylate-342037#10